A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Todd Michael Bauer, Douglas Adkins, Gary K. Schwartz, Theresa Louise Werner, Ajjai Shivaram Alva, David S. Hong, Richard D. Carvajal, Mansoor N. Saleh, Lyudmila Bazhenova, Sanjay Goel, Keith D. Eaton, Robert D. Siegel, Ding Wang, Richard C. Lauer, Saskia T.C. Neuteboom, Demiana Faltaos, Isan Chen, James Christensen, Richard C. Chao, Rebecca Suk Heist
Institutions: Tennessee Oncology, Washington University in St. Louis, Columbia University Irving Medical Center, University of Utah, University of Michigan, The University of Texas MD Anderson Cancer Center, University of Alabama at Birmingham, Moores Cancer Center, Albert Einstein College of Medicine, Montefiore Medical Center, Montefiore Einstein Comprehensive Cancer Center, University of Washington, Henry Ford Health, UNM Comprehensive Cancer Center, Mirati Therapeutics (United States), Massachusetts General Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2746946561